Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry

被引：7

作者：

Chang, Te-Sheng ^{[1
,2
]}

Huang, Chung-Feng ^{[3
,4
,5
]}

Kuo, Hsing-Tao ^{[6
]}

Lo, Ching-Chu ^{[7
]}

Huang, Chien-Wei ^{[8
]}

Chong, Lee-Won ^{[9
,10
]}

Cheng, Pin-Nan ^{[11
]}

Yeh, Ming-Lun ^{[3
,4
,12
]}

Peng, Cheng-Yuan ^{[13
,14
]}

Cheng, Chien-Yu ^{[15
]}

Huang, Jee-Fu ^{[3
,4
,16
]}

Bair, Ming-Jong ^{[17
,18
]}

Lin, Chih-Lang ^{[19
,20
]}

Yang, Chi-Chieh ^{[21
]}

Wang, Szu-Jen ^{[22
]}

Hsieh, Tsai-Yuan ^{[23
]}

Lee, Tzong-Hsi ^{[24
]}

Lee, Pei-Lun ^{[25
]}

Wu, Wen-Chih ^{[26
]}

Lin, Chih-Lin ^{[27
]}

Su, Wei-Wen ^{[28
]}

Yang, Sheng-Shun ^{[29
,30
,31
]}

Wang, Chia-Chi ^{[4
,32
,33
]}

Hu, Jui-Ting ^{[34
]}

Mo, Lein-Ray ^{[35
]}

Chen, Chun-Ting ^{[36
]}

Huang, Yi-Hsiang ^{[37
,38
]}

Chang, Chun-Chao ^{[39
,40
]}

Huang, Chia-Sheng ^{[41
]}

Chen, Guei-Ying ^{[42
]}

Kao, Chien-Neng ^{[43
]}

Tai, Chi-Ming ^{[44
,45
]}

Liu, Chun-Jen ^{[46
,47
]}

Lee, Mei-Hsuan ^{[48
]}

Tsai, Pei-Chien ^{[3
]}

Dai, Chia-Yen ^{[3
]}

Kao, Jia-Horng ^{[46
,47
]}

Lin, Han-Chieh

Chuang, Wang-Long ^{[3
,4
]}

Chen, Chi-Yi ^{[49
]}

Tseng, Kuo-Chih ^{[50
,51
]}

Hung, Chao-Hung ^{[52
]}

Yu, Ming-Lung ^{[3
,4
,12
,52
,53
]}

机构：

[1] Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Chiayi, Taiwan

[2] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Dept Internal Med,Hepatobiliary Div, Kaohsiung, Taiwan

[4] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Hepatitis Ctr, Kaohsiung, Taiwan

[5] Kaohsiung Med Univ, Acad Sinica, Coll Med, PhD Program Translat Med, Kaohsiung, Taiwan

[6] Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan, Taiwan

[7] St Martin De Porres Hosp, Dept Internal Med, Div Gastroenterol, Chiayi, Taiwan

[8] Kaohsiung Armed Forces Gen Hosp, Div Gastroenterol, Kaohsiung, Taiwan

[9] Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Div Hepatol & Gastroenterol, Taipei, Taiwan

[10] Fu Jen Catholic Univ, Sch Med, New Taipei City, Taiwan

[11] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med,Div Gastroenterol & Hepatol, Tainan, Taiwan

[12] Kaohsiung Med Univ, Ctr Liquid Biopsy & Cohort Res, Kaohsiung, Taiwan

[13] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, Taichung, Taiwan

[14] China Med Univ, Sch Med, Taichung, Taiwan

[15] Minist Hlth & Welf, Taoyuan Gen Hosp, Dept Internal Med, Div Infect Dis, Taoyuan, Taiwan

[16] Kaohsiung Med Univ, Coll Med, Hepatitis Res Ctr, Kaohsiung, Taiwan

[17] Taitung Mackay Mem Hosp, Dept Internal Med, Div Gastroenterol, Taitung, Taiwan

[18] Mackay Med Coll, New Taipei City, Taiwan

[19] Chang Gung Univ, Chang Gung Mem Hosp Keelung, Coll Med, Dept Hepatogastroenterol,Liver Res Unit, Keelung, Taiwan

[20] Chang Gung Univ, Chang Gung Mem Hosp Keelung, Coll Med, Community Med Res Ctr, Keelung, Taiwan

[21] Show Chwan Mem Hosp, Dept Gastroenterol, Div Internal Med, Changhua, Taiwan

[22] Yuans Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan

[23] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan

[24] Far Eastern Mem Hosp, Div Gastroenterol & Hepatol, New Taipei City, Taiwan

[25] Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan, Taiwan

[26] Wen Chih Wu Clin, Kaohsiung, Taiwan

[27] Taipei City Hosp, Dept Gastroenterol, Renai Branch, Taipei, Taiwan

[28] Changhua Christian Hosp, Dept Gastroenterol & Hepatol, Changhua, Taiwan

[29] Taichung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taichung, Taiwan

[30] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan

[31] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan

[32] Tzu Chi Univ, Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Taipei, Taiwan

[33] Tzu Chi Univ, Sch Med, Taipei, Taiwan

[34] Cathay Gen Hosp, Liver Ctr, Taipei, Taiwan

[35] Show Chwan Med Care Corp, Tainan Municipal Hosp, Div Gastroenterol, Tainan, Taiwan

[36] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Gastroenterol,Penghu Branch, Taipei, Taiwan

[37] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol & Hepatol, Taipei, Taiwan

[38] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Sch Med, Taipei, Taiwan

[39] Taipei Med Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taipei, Taiwan

[40] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med,Div Gastroenterol & Hepatol, Taipei, Taiwan

[41] Yang Ming Hosp, Chiayi, Taiwan

[42] Minist Hlth & Welf, Penghu Hosp, Penghu, Taiwan

[43] Natl Taiwan Univ Hosp, Hsin Chu Branch, Hsinchu, Taiwan

[44] E Da Hosp, Dept Internal Med, Kaohsiung, Taiwan

[45] I Shou Univ, Coll Med, Sch Med, Kaohsiung, Taiwan

[46] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan

[47] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[48] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan

[49] Ditmanson Med Fdn Chiayi Christian Hosp, Dept Med, Div Gastroenterol & Hepatol, Chiayi, Taiwan

[50] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Internal Med, Chiayi, Taiwan

来源：

HEPATOLOGY INTERNATIONAL | 2023年 / 17卷 / 03期

关键词：

Compensated cirrhosis; GLE; PIB; HCV; Sustained virologic response; C VIRUS-INFECTION; THERAPY;

D O I：

10.1007/s12072-023-10506-z

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BackgroundLarge-scale real-world data of the 8-week glecaprevir/pibrentasvir (GLE/PIB) therapy for treatment-naive patients of chronic hepatitis C virus (HCV) infection with compensated cirrhosis is scarce.MethodsThe TASL HCV Registry (TACR) is an ongoing nationwide registry program that aims to set up a database and biobank of patients with chronic HCV infection in Taiwan. In this study, data were analyzed as of 31 October 2021 for treatment-naive HCV patients with compensated cirrhosis receiving 8-week GLE/PIB therapy. Effectiveness reported as sustained virologic response at off-therapy week 12 (SVR12) and safety profiles were assessed. Patient characteristics potentially related to SVR12 were also evaluated.ResultsOf the 301 patients enrolled, 275 had available SVR12 data. The SVR12 rate was 98.2% (270/275) in the modified intention-to-treat (mITT) population and 89.7% (270/301) in the ITT population. For those mITT patients with genotype 3, FibroScan > 20 kPa, platelet < 150,000/mu l, and FibroScan > 20 kPa and platelet < 150,000/mu l, the SVR12 rates were 100% (6/6), 100% (12/12), 98.0% (144/147), 100% (7/7), respectively. Overall, 24.9% (75/301) patients experienced adverse events (AEs). The most frequent AEs (> 5%) included fatigue (9.0%) and pruritus (7.0%). Seven (2.3%) patients experienced serious AEs and two (0.7%) resulted in permanent drug discontinuation. None of them were considered as GLE/PIB-related.ConclusionsIn this large-scale real-world Taiwanese cohort, 8-week GLE/PIB therapy was efficacious and well tolerated for treatment-naive compensated cirrhosis patients. SVR12 rates were similarly high as in the clinical trials, including those with characteristics of advanced liver disease.

引用

页码：550 / 561

页数：12

共 50 条

[31] Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
Zarebska-Michaluk, Dorota
Jaroszewicz, Jerzy
Pabjan, Pawel
Lapinski, Tadeusz W.
Mazur, Wlodzimierz
Krygier, Rafal
Dybowska, Dorota
Halota, Waldemar
Pawlowska, Malgorzata
Janczewska, Ewa
Buczynska, Iwona
Simon, Krzysztof
Dobracka, Beata
Citko, Jolanta
Laurans, Lukasz
Tudrujek-Zdunek, Magdalena
Tomasiewicz, Krzysztof
Piekarska, Anna
Sitko, Marek
Bialkowska-Warzecha, Jolanta
Klapaczynski, Jakub
Sobala-Szczygiel, Barbara
Horban, Andrzej
Berak, Hanna
Deron, Zbigniew
Lorenc, Beata
Socha, Lukasz
Tronina, Olga
Flisiak, Robert
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (07) : 1944 - 1952
[32] Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
Markus Cornberg
Adriana Ahumada
Alessio Aghemo
Massimo Andreoni
Abhi Bhagat
Isabel Butrymowicz
Michal Carmiel
Gabriel Chodick
Brian Conway
Yanna Song
Antonio Gasbarrini
Dietrich Hüppe
Francisco Jorquera Plaza
Pietro Lampertico
Maria Luisa Manzano Alonso
Lindsay Myles
Marcello Persico
Alnoor Ramji
Christoph Sarrazin
Erica Villa
Clara Weil
Juan Isidro Uriz Otano
Advances in Therapy, 2022, 39 : 3146 - 3158
[33] Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older
Huff, Jamie
Andersen, Rebecca
ANNALS OF PHARMACOTHERAPY, 2020, 54 (03) : 262 - 276
[34] Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry
Klinker, Hartwig
Naumann, Uwe
Roessle, Martin
Berg, Thomas
Bondin, Mark
Lohmann, Kristina
Koenig, Bettina
Zeuzem, Stefan
Cornberg, Markus
LIVER INTERNATIONAL, 2021, 41 (07) : 1518 - 1522
[35] Real-world effectiveness and safety of glecaprevir plus pibrentasvir in HCV: A multi-country analysis of postmarketing observational studies
Lampertico, Pietro
Peck, Markus
Bondin, Mark
Horsmans, Yves
Semmo, Nasser
Sonparote, Sadhana
Zhang, Zhenzhen
Porcalla, Ariel
Thabut, Dominique
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E228 - E228
[36] Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
Liu, Chen-Hua
Liu, Chun-Jen
Hung, Chien-Ching
Hsieh, Szu-Min
Su, Tung-Hung
Sun, Hsin-Yun
Tseng, Tai-Chung
Chen, Pei-Jer
Chen, Ding-Shinn
Kao, Jia-Horng
LIVER INTERNATIONAL, 2020, 40 (04) : 758 - 768
[37] EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND COMPENSATED CIRRHOSIS: EXPEDITION-8 COMPLETE RESULTS
Brown, Robert S., Jr.
Buti, Maria
Rodrigues, Lino
Chulanov, Vladimir
Chuang, Wan Long
Aguilar, Humberto
Horvath, Gabor
Zuckerman, Elimelech
Rosado-Carrion, Barbara
Rodriguez-Perez, Federico
Urbanek, Petr
Abergel, Armand
Cohen, Eric
Lovell, Sandra Sinisi
Schnell, Gretja
Lin, Chih-Wei
Zha, Jiuhong
Wang, Stanley
Trinh, Roger
Mensa, Federico J.
Burroughs, Margaret
Felizarta, Franco
HEPATOLOGY, 2019, 70 (06) : 1493A - 1494A
[38] Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Steven L. Flamm
Jens Kort
Steven E. Marx
John Strezewski
Douglas E. Dylla
Bruce Bacon
Michael P. Curry
Naoky Tsai
Nicole Wick
Advances in Therapy, 2020, 37 : 2267 - 2274
[39] Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis
Flamm, Steven L.
Wyles, David L.
Wang, Stanley
Mutimer, David J.
Rockstroh, Jrgen K.
Horsmans, Yves J.
Kwo, Paul Y.
Weiland, Ola
Villa, Erica
Heo, Jeong
Gane, Edward J.
Ryder, Stephen D.
Welzel, Tania M.
Ng, Teresa
Lovell, Sandra S.
Liu, Ran
Krishnan, Preethi
Kopecky-Bromberg, Sarah
Asatryan, Armen
Trinh, Roger
Mensa, Federico J.
HEPATOLOGY, 2017, 66 : 35A - 36A
[40] Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study
Aghemo, Alessio
Persico, Marcello
D'Ambrosio, Roberta
Andreoni, Massimo
Villa, Erica
Bhagat, Abhi
Gallinaro, Valentina
Gualberti, Giuliana
Merolla, Rocco Cosimo Damiano
Gasbarrini, Antonio
PLOS ONE, 2023, 18 (02):

← 1 2 3 4 5 →